Merck Patent Gesellschaft MIT Beschrankter Haftung

Other

Merck Patent Gmbh

Merck Patent Gesellschaft

Merck Patent Gesellschaft MIT Beschraenkter Haftung

3-dimensional Pharmaceuticals, Inc.

Ralf M Devant

Werner Mederski

Richard M Soll

Gerd Bartoszyk

Mark R Player

Bertram Cezanne

Daljit Singh Dhanoa

Sabine Bernotat-Danielowski

James M Rinker

Bao-Ping Zhao

Gerhard Barnickel

Christoph Seyfried

Rolf Gericke

Hartmut Greiner

Henning Bottcher

Henning Böttcher

Guido Melzer

Jean-Jacques Berthelon

Steffen Neuenfeld

Michel Brunet

Jean-Jacques Zeiller

Heinz-Hermann Bokel

Hermann Russ

Frank Weber

Ralf Knierieme

Marc Noblet

Maria Devant, Legal Representative

Ludwig Gantzert

James Vickers

Helmut Reubold

Edward Jaeger

Elke Simon

Udo Helm

4-amino-quinazolines

Compounds of formula I in which R has a meaning as indicated in claim, or one of their optical isomers or pharmaceutically acceptable salts, used for the treatment of extrapyramidal movement disorders and/or adverse effects in extrapyramidal movement disorders and/or for the treatment of extrapyramidal symptoms (EPS) induced by neuroleptics. 

Use of substituted aminomethyl chromans

Quinazolinones of formula (I) in which R, R, R, R, R, Y, n and m have the meaning indicated in Patent claim 1, and their salts or solvates as glycoprotein IbIX antagonists

Quinazolinones

The present invention relates to a process for the preparation of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chroman, the enantiomers and its salts, characterised in that 5-(4-fluorophenyl)pyridine-3-carbaldehyde is reacted directly with aminomethylchroman or its salts under reducing conditions to give 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chroman, and the latter is, if desired, converted into one of its physiologically acceptable salts by treatment with an acid.

Method for producing-2[-5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane

Amino(thio)ether derivatives of formula I ##STR1## wherein R.sup.0, R.sup.1, R.sup.2, R.sup.3, R.sup.6, R.sup.7, R.sup.8, R.sup.9, X and Z are as defined herein, and their salts, are active on the central nervous system.

Pyridyl chroman

The invention relates to a process for the resolution of enantiomers of 3,4-epoxy-3,4-dihydro-2,2-dimethyl-3-R-2H-1-benzopyran-6-carbonitriles (I), in which R is H or CH.sub.3, characterized in that racemic I is dissolved in an inert solvent or solvent mixture together with a small amount of (-)-I [or (+)-I], the solution is seeded with (-)-I [or (+)-I], the precipitated (-)-I [or (+)-I] is isolated, further racemic I is dissolved in the filtrate, seeded with (+)-I [or (-)-I], the precipitated (+)-I [or (-)-I] is isolated and, if desired, this crystallization cycle is repeated one or more times.

Process for the resolution of enantiomers of benzopyran derivatives

The invention relates to a process for resolving the enantiomers of trans-3-hydroxy-3,4-dihydro-2,2-dimethyl-4-(2-oxo-1,2-dihydropyridin-1-yl) -2H -1-benzopyran-6-carbonitrile (I), characterized in that racemic I, together with a small amount of (-)-I [or (+)-I], is dissolved in an inert solvent or solvent mixture, the solution is seeded with (-)-I [or (+)-I], the (-)-I [or (+)-I] which has precipitated is isolated, further racemis I is dissolved in the filtrate, the mixture is seeded with (+)-I [or (-)-I], the (+)-I [or (-)-I] which has precipitated is isolated, and if desired this crystallization cycle is repeated once or several times.

Process for resolving the enantiomers of a benzopyran derivative

Growing community of inventors

Darmstadt-Arheilgen, Germany

Ralf M Devant